Active Biotech — Report Publication Announcement 2012

Apr 17, 2012

PRESS RELEASE

Annual Report 2011 Active Biotech AB (publ)

Active Biotech's Annual Report 2011 (in Swedish) is now available for download at www.activebiotech.com.

The Annual Report will only be digitally distributed.

Lund, April 17, 2012

Active Biotech AB (publ)

Tomas Leanderson President & CEO

For further information, please contact: Hans Kolam CFO Tel +46 (0)46 19 20 44

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex® for RA. Please visit http://www.activebiotech.com for more information.

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00

Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act. This information was provided to the media for publication on April 17, 2012, at 10:00 a.m.